Oxford Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Oxford Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,345	Closed	-$1.19M	–	1738
2019 Q3	$1.19M	Buy	+12,345	New	+$1.38M	0.03%	842
2018 Q3	–	Sell	-11,555	Closed	-$770K	–	1682
2018 Q2	$770K	Buy	+11,555	New	+$760K	0.01%	1158
2018 Q1	–	Sell	-9,466	Closed	-$384K	–	1598
2017 Q4	$384K	Buy	+9,466	New	+$344K	0.01%	1270

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Oxford Asset Management's ASND Position: Q4 2019 in Review

Oxford Asset Management sold out of Ascendis Pharma A/S (ASND) in Q4 2019, closing a stake of 12,345 shares — an estimated $1.19M sold.

Oxford Asset Management first reported a position in ASND in Q4 2017 and held it in 3 quarters. The position peaked at $1.19M in Q3 2019. 143 funds tracked by Wall St. Rank hold ASND as of Q4 2019.

Oxford Asset Management reported no remaining Ascendis Pharma A/S position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 12,345 Ascendis Pharma A/S shares in Q4 2019, an estimated $1.19M.
Oxford Asset Management first reported a position in Ascendis Pharma A/S in Q4 2017 and held it in 3 quarters.
Oxford Asset Management's Ascendis Pharma A/S position peaked at $1.19M in Q3 2019.
143 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.